Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Kadcyla Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0115

    Kadcyla (ado-trastuzumab) coverage

    Customize your policy alerts

    Sign up for Anthem Policy CC-0115 alerts

    Get alerted when Policy CC-0115 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical medical policy defining prior authorization and medical necessity criteria for Kadcyla (ado-trastuzumab emtansine) across HER2-positive oncology indications including breast cancer, NSCLC, brain metastases, head & neck and salivary gland tumors for Anthem members.

    Policy Summary
    PayerAnthem
    PolicyKadcyla (ado-trastuzumab) coverage
    Policy CodePolicy CC-0115
    Change TypeRevised — clinical criteria and coding updates (material changes)
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date02/20/2027
    Key ActionSubmit prior authorization with documented HER2 positivity (IHC 3+ or ISH positive) and prior trastuzumab ± taxane exposure when required.
    SourceLink
    POLICY UPDATE CHANGES

    Updated NCCN recommendation for use in brain metastases with HER2-positive breast cancer to allow combination with neratinib and clarified use timing.

    Updated NCCN recommendation for use in NSCLC to ensure individuals are not switching between drugs with similar mechanisms of action at progression.

    Clarified trastuzumab biosimilars are considered equivalent where referenced in prior anti-HER2 therapy requirements.

    Coding range for breast cancer ICD-10 codes expanded (added C50.A0-C50.A2 to existing range); removal of C79.81.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NCCN 1/2A/2AGuideline levels cited
    DefinedHER2 testing
    MultipleTumor types
    RevisedLast review